Volkow: why pain and addiction will go personalized

Why NIDA director Nora Volkow thinks pain and addiction need personalized approaches

While addiction still carries a social stigma, neuroscience research not only supports the view that it is a disease, but is starting to paint a more nuanced picture of the variety of mechanistic pathways involved. Nora Volkow, director of NIH’s National Institute on Drug Abuse, thinks a personalized approach to the condition is warranted to address the different biological disease processes operating in different patients.

Volkow has headed up NIDA since 2003 and has championed a complex definition of addiction that neither reduces it solely to a behavioral problem nor to a biological one. She has also advocated for a multipronged approach to therapeutics development, as there is likely to be no one-size-fits-all solution (see “Addiction Camps”).

According to Volkow, the preponderance of evidence suggests that individuals have different susceptibilities to addiction, based on a constellation of biological, behavioral, social and economic factors. Moreover, the biological risks are diverse, involving genetics, epigenetics, and the wiring and fine-tuning of synaptic circuits throughout the brain, not just dopamine signaling.

That means engaging in drug taking is riskier for some people than for others, and that not everyone

Read the full 1835 word article

User Sign In